Core Viewpoint - The article discusses the investment potential of Thermo Fisher Scientific (TMO) in the context of changing macroeconomic conditions, particularly the impact of U.S.-China trade tensions and the post-COVID normalization phase [1]. Company Analysis - Thermo Fisher Scientific is positioned to benefit from a reacceleration in growth following the normalization after the COVID-19 pandemic [1]. - The company operates in a sector characterized by high barriers to entry, making it an attractive investment opportunity [1]. Industry Context - The current macro environment is marked by renewed trade tensions between the U.S. and China, which could influence the operational landscape for companies like Thermo Fisher Scientific [1]. - The article highlights the importance of understanding the broader economic factors that may affect the performance of companies in the life sciences and diagnostics sectors [1].

Investment Rating - The report maintains a "BUY" rating for Thermo Fisher, indicating a potential return of over 15% over the next 12 months [15]. Core Insights - Thermo Fisher reported a revenue increase of 0.2% year-over-year to US$10.4 billion in 1Q25, with adjusted EPS rising 0.8% year-over-year to US$5.15, both exceeding Bloomberg consensus estimates [1]. - The company has revised its full-year revenue guidance to project growth between 1.0% and 3.1% for 2025, while adjusting its EPS guidance downward, expecting a range from a 0.6% decline to 4.4% growth due to macroeconomic factors [1][7]. - Management anticipates a US$500 million reduction in revenue guidance due to US policy changes affecting equipment sales, alongside a projected US$400 million revenue reduction from elevated tariffs between the US and China [7]. Financial Summary - For FY25E, revenue is estimated at US$43.806 billion, reflecting a 2.2% year-over-year growth, with adjusted net profit expected to be US$8.461 billion, a 2.5% increase [2][12]. - The adjusted EPS for FY25E is projected at US$22.42, with a P/E ratio of 19.3x [2][12]. - The company plans to invest US$2 billion over the next four years to expand its US manufacturing and R&D facilities, aiming to support long-term growth and market share expansion [7]. Valuation - The target price for Thermo Fisher has been revised down from US$690.00 to US$526.00, representing a 21.9% upside from the current price of US$431.64 [3]. - The DCF valuation indicates a total present value of US$226 billion, with an equity value of US$198.5 billion, leading to a price per share of US$526.00 [10].

Core Insights - Thermo Fisher Scientific Inc. reported first-quarter 2025 adjusted earnings per share (EPS) of $5.15, exceeding the Zacks Consensus Estimate by 1% and reflecting a year-over-year increase of 0.8% [1] - The company's GAAP EPS was $3.98, marking a 15% increase year over year [1] - Following the earnings announcement, shares of Thermo Fisher rose 1.7% in pre-market trading [2] Revenue Performance - Total revenues for the quarter reached $10.36 billion, a 0.2% increase year over year, surpassing the Zacks Consensus Estimate by 1.1% [3] - Organic revenues increased by 1% year over year [3] Segment Analysis - Life Sciences Solutions segment (22.6% of total revenues) saw revenues increase by 2.4% year over year to $2.34 billion, exceeding estimates [4] - Analytical Instruments segment (16.6%) reported a 1.8% year-over-year increase in revenues to $1.72 billion, which fell short of estimates [5] - Specialty Diagnostics segment (11.1%) experienced a 3.5% year-over-year revenue increase to $1.15 billion, surpassing predictions [6] - Laboratory Products and Biopharma Services segment (54.4%) saw a decline of 1.4% year over year, with revenues at $5.64 billion, slightly below estimates [7] Margin Performance - Gross margin for the first quarter was 41.6%, contracting by 5 basis points year over year due to a 0.3% rise in the cost of revenues [8] - Selling, general and administrative expenses decreased by 0.6% to $1.72 billion, while research and development expenses increased by 3.3% to $342 million [8] - Adjusted operating margin was 21.7%, reflecting a contraction of 2 basis points [8] Financial Position - At the end of Q1 2025, cash and cash equivalents and short-term investments totaled $5.95 billion, up from $5.57 billion at the end of Q4 2024 [9] - Net cash from operating activities was $723 million, down from $1.25 billion a year ago [10] - The company has a consistent dividend-paying history, with a five-year annualized dividend growth of 15.10% [10] Strategic Developments - During the first quarter, Thermo Fisher launched several innovative products, including the Thermo Scientific Vulcan Automated Lab and Olink Reveal proteomics kits, contributing to commercial success [12] - The company announced an agreement to acquire Solventum's Purification & Filtration Business for $4.1 billion in cash [12] Overall Assessment - Thermo Fisher's first-quarter results exceeded expectations in terms of earnings and revenues, with growth in most segments except for Laboratory Products and Biopharma Services [11] - The contraction in margins was noted as a concern, and the company is expected to provide guidance for 2025 in an upcoming earnings call [11]

Core Viewpoint - Thermo Fisher Scientific Inc. reported strong first-quarter 2025 results, with adjusted earnings per share of $5.15, surpassing analyst expectations of $5.10, and quarterly sales of $10.36 billion, slightly above the consensus estimate of $10.23 billion [1][2] Financial Performance - Adjusted operating income for Q1 2025 was $2.27 billion, a slight decrease from $2.28 billion in the same quarter last year [3] - Adjusted operating margin was 21.9%, down from 22% in Q1 2024 [3] - Organic revenue growth was recorded at 1% [1] Segment Performance - Life Sciences Solutions Segment revenue increased by 2.5% year over year to $2.34 billion [3] - Analytical Instruments Segment sales rose by 1.8% to $1.72 billion [3] - Specialty Diagnostics Segment revenues grew by 3.5% to $1.15 billion [4] - Laboratory Products and Biopharma Services segment sales decreased by 1.5% to $5.64 billion [4] Strategic Developments - The company announced an agreement to acquire Solventum's SOLV Purification & Filtration business for approximately $4.1 billion in cash, which focuses on purification and filtration technologies for biologics and medical technologies [4] Market Reaction - Following the earnings report, Thermo Fisher's stock price increased by 4.23%, reaching $453.10 [5]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $10.36 billion, with adjusted operating income of $2.27 billion and an adjusted operating margin of 21.9% [10][11] - Adjusted EPS grew by 1% to $5.15 per share, while GAAP EPS increased by 15% to $3.98 [36] - Organic revenue growth was approximately $100 million or 1% ahead of expectations, with reported revenue flat year over year [35][37] Performance by Business Lines - Life Science Solutions reported a 2% increase in revenue, driven by bioproduction, but adjusted operating income decreased by 1% [43][44] - Analytical Instruments saw a 2% revenue growth, led by electron microscopy, with adjusted operating income flat year over year [45][46] - Specialty Diagnostics grew by 3% in revenue, with adjusted operating income increasing by 3% [46][47] - Laboratory Products and Biopharma Services experienced a 1% decrease in both reported and organic revenue, primarily due to the runoff of pandemic-related revenue [48] Market Data and Key Metrics Changes - North America revenue was flat year over year, while Europe and Asia Pacific grew low single digits, with China declining mid-single digits [38] - Academic and government revenue declined low single digits due to macro conditions in the U.S. and China [12][13] Company Strategy and Development Direction - The company’s growth strategy focuses on high-impact innovation, trusted partner status with customers, and a strong commercial engine [14][18] - Recent product launches include the Thermo Scientific Vulcan automated lab and the next-generation Thermo Scientific Transcend platform, enhancing market leadership [15][17] - The company is actively managing its supply chain to mitigate tariff impacts and is investing $2 billion in U.S. manufacturing and R&D [31][41] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a more uncertain macro environment but emphasized strong execution and customer success [8][9] - Updated guidance for 2025 includes revenue expectations of $43.3 billion to $44.2 billion and adjusted EPS in the range of $21.76 to $22.84 [26][61] - Management remains optimistic about long-term growth despite current challenges, citing strong demand for healthcare and scientific breakthroughs [87][89] Other Important Information - The company repurchased $1 billion of shares and increased its dividend by 10% during the quarter [24] - The acquisition of SOVENTUM's purification and filtration business for $4.1 billion is expected to close by the end of 2025 [22][23] Q&A Session Summary Question: Guidance methodology in light of market uncertainty - Management acknowledged the dynamic nature of the macro environment and emphasized their agility in navigating risks and capitalizing on opportunities [72][76] Question: Long-term growth outlook for the tools market - Management expressed optimism about long-term growth driven by healthcare demand and scientific advancements, despite potential short-term challenges [84][87] Question: Changes in order behavior due to tariffs - Management noted that there has not been a significant pull forward in orders due to the short notice of tariff announcements [93][94] Question: Flexibility in manufacturing - Management highlighted the company's robust manufacturing capabilities and flexibility across different product types, which positions them well to adapt to changes [96][101] Question: Impact of pharmacy tariffs - Management indicated ongoing discussions with pharmaceutical customers regarding tariffs and emphasized the importance of U.S. manufacturing capabilities [105][106] Question: Breakdown of policy-related guidance reduction - Management clarified that $200 million of the guidance reduction was due to canceled vaccine-related studies, with the remainder reflecting softer academic and government spending [114][115] Question: Pricing assumptions in light of tariffs - Management stated that they are implementing appropriate pricing actions to mitigate tariff impacts, expecting a slight increase in pricing across the portfolio [120][121]

Core Insights - Thermo Fisher Scientific reported revenue of $10.36 billion for the quarter ended March 2025, reflecting a year-over-year increase of 0.2% and an EPS of $5.15, up from $5.11 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $10.25 billion by 1.11%, while the EPS surpassed the consensus estimate of $5.10 by 0.98% [1] Revenue Performance - Organic revenue growth was 1%, compared to the average estimate of 0.2% from five analysts [4] - Life Sciences Solutions revenue was $2.34 billion, exceeding the estimated $2.28 billion, representing a year-over-year increase of 2.5% [4] - Analytical Instruments revenue was $1.72 billion, slightly below the estimated $1.73 billion, with a year-over-year increase of 1.8% [4] - Laboratory Products and Biopharma Services revenue was $5.64 billion, slightly above the estimated $5.61 billion, but showed a year-over-year decline of 1.5% [4] - Specialty Diagnostics revenue was $1.15 billion, surpassing the estimated $1.10 billion, with a year-over-year increase of 3.5% [4] - Revenues from Eliminations were reported at -$482 million, worse than the average estimate of -$449.31 million, but showed a year-over-year improvement of 4.8% [4] Stock Performance - Thermo Fisher's shares have returned -15.5% over the past month, compared to a -6.6% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Company Performance - Thermo Fisher Scientific reported quarterly earnings of $5.15 per share, exceeding the Zacks Consensus Estimate of $5.10 per share, and showing a slight increase from $5.11 per share a year ago [1] - The company achieved revenues of $10.36 billion for the quarter, surpassing the Zacks Consensus Estimate by 1.11%, and showing a marginal increase from $10.35 billion year-over-year [3] - Over the last four quarters, Thermo Fisher has consistently surpassed consensus EPS estimates four times and revenue estimates three times [2][3] Market Outlook - The stock has underperformed, losing approximately 16.4% since the beginning of the year, compared to a decline of 10.1% for the S&P 500 [4] - The current consensus EPS estimate for the upcoming quarter is $5.56, with expected revenues of $10.78 billion, and for the current fiscal year, the EPS estimate is $23.17 on revenues of $43.82 billion [8] Industry Context - The Medical - Instruments industry, to which Thermo Fisher belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [9] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [6]

Core Viewpoint - Analysts project that Thermo Fisher Scientific (TMO) will report quarterly earnings of $5.10 per share, reflecting a 0.2% decline year over year, with revenues expected to reach $10.25 billion, down 0.9% from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating a reassessment by covering analysts [1][2]. - Revisions to earnings estimates are crucial for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [2]. Revenue Projections - Analysts forecast 'Revenues- Laboratory Products and Biopharma Services' to reach $5.61 billion, indicating a decline of 2.1% from the prior-year quarter [4]. - 'Revenues- Specialty Diagnostics' is expected to be $1.10 billion, reflecting a decrease of 0.5% year over year [4]. - 'Revenues- Life Sciences Solutions' is projected at $2.28 billion, showing a year-over-year change of -0.3% [4]. Geographic Revenue Estimates - 'Revenues- Analytical Instruments' is expected to reach $1.73 billion, suggesting a year-over-year increase of 2.5% [5]. - 'Geographic Revenues- Customer Location- North America' is projected at $5.43 billion, indicating a decline of 1.7% year over year [5]. - 'Geographic Revenues- Customer Location- Asia-Pacific' is estimated at $1.88 billion, reflecting a growth of 0.8% [5]. - 'Geographic Revenues- Customer Location- Other regions' is expected to reach $368.42 million, indicating a year-over-year increase of 6.5% [6]. - 'Geographic Revenues- Customer Location- Europe' is projected at $2.60 billion, reflecting a decrease of 0.7% from the year-ago quarter [6]. Stock Performance - Shares of Thermo Fisher have shown a return of -15.7% over the past month, compared to a -6.3% change in the Zacks S&P 500 composite [6].

Core Viewpoint - Thermo Fisher Scientific Inc. is expected to report first-quarter 2025 results on April 23, with a consensus estimate for revenues at $10.25 billion, indicating a 0.9% decline year-over-year, and earnings per share (EPS) at $5.10, reflecting a 0.2% decline from the previous year [1][2]. Revenue Estimates - The Zacks Consensus Estimate for Thermo Fisher's first-quarter revenues is $10.25 billion, suggesting a 0.9% decline from the prior-year quarter [1]. - The Analytical Instruments segment is projected to generate $1.78 billion in revenues, indicating a 5.8% growth year-over-year [5]. - The Life-Science Solutions business is expected to report $2.16 billion in revenues, reflecting a 5.4% decline year-over-year [8]. - The Specialty Diagnostics segment is anticipated to generate $1.09 billion in revenues, suggesting a 1.6% decline year-over-year [10]. - The Laboratory Products and Services segment is expected to report revenues of $5.65 billion, down 1.2% year-over-year [12]. Factors Influencing Performance - Strong sales are anticipated in the Analytical Instruments segment, driven by electron microscopy and chromatography and mass spectrometry businesses, including the launch of the Invitrogen EVOS S1000 Spatial Imaging System [3]. - The Life-Science Solutions segment is likely to benefit from sales growth in bioproduction and biosciences, with notable developments such as the Olink Explore Platform being selected for a major human proteomics study [6]. - The bioproduction business is expected to grow due to strong adoption in the pharma and biotech sectors, supported by the introduction of the Accelerator Drug Development solution [7]. - The Specialty Diagnostics segment is expected to gain from contributions in transplant diagnostics and immunodiagnostics, along with new registry launches [9]. - The Laboratory Products and Services segment is projected to see revenue increases due to the research and safety market, with new product launches aimed at semiconductor manufacturing [11]. Estimate Revision Trend - Estimates for Thermo Fisher's first-quarter earnings have decreased by 0.2% to $5.10 per share over the past 30 days [2].

Core Insights - The article emphasizes the importance of identifying good companies at bargain prices for long-term returns and dividends in various investing climates [1] Group 1 - Grant Gigliotti, the founder of Beat The Market Analyzer, has over 20 years of experience in active investing and focuses on value investing strategies similar to those of Warren Buffett [2] - The goal is to demonstrate how to purchase companies with strong fundamentals at significant discounts from their intrinsic value [2]